Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220109) titled 'A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease' on Oct. 21.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: GlaxoSmithKline
Condition:
Respiratory Syncytial Virus Infections
Intervention:
Biological: RSVPreF3 OA vaccine
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First...